Zacks Investment Research
25 Sept 2025, 15:51 UTC · 51w ago
Verdict
Headline takes no side. We score ACAD −0.60 across four claims — strongly bearish.
−0.60strongly bearish
More negative than 83% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Acadia Pharmaceuticals' Phase III COMPASS PWS study for intranasal carbetocin (ACP-101) failed to meet its primary and secondary endpoints.
More negative than 92% of claims this week
Acadia Pharmaceuticals has decided to permanently cease further investigation of ACP-101 following the failed study.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 81% of claims this week
Acadia's approved products, Nuplazid and Daybue, are projected to generate over $1 billion in net sales by 2025.
So whatStrong revenue guidance from existing commercial products provides a fundamental floor for the company's valuation.
More positive than 64% of claims this week
Nuplazid recorded $328.2 million in H1 2025 sales, a 14% year-over-year increase driven by volume growth.
More positive than 52% of claims this week
Which stocks this story touches
More negative than 83% of ticker scores this week
The company reported a failed phase III study for ACP-101 and shares dropped 9.9%, though existing product sales remain strong.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Reuters
1d ago
+28.4%
Price is moving against the score
$27.29 vs $21.26 close before publication (Sep 24) · not market-adjusted
ACAD chart →
